Bacteriophage Therapy for Morganella Morganii Prosthetic Joint Infection

Condition(s) studied

Investigational drug(s) / intervention(s)

phage therapy: Single anti-Morganella morganii bacteriophage drug product

Study summary

This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage drug product to treat and prevent the recurrence of a Morganella morganii prosthetic joint infection of the hip. The patient has exhausted all conventional therapies, both surgical and medical, at considerable detriment to their quality of life. The treatment involves 2 intra-articular injections of bacteriophages into the joint and surrounding area and 14 days of intravenous phage therapy. The goal is to eliminate the infection and prevent further complications, providing a potential new treatment avenue for patients with difficult-to-treat infections.

Eligibility

Primary outcome measure(s)

• Clinical response to phage therapy as determined by participant's absence of physical symptoms — 1 year
  Resolution of the infection, indicated by the absence of clinical symptoms such as wound drainage, swelling, erythema, pain, and fever. This will be determined by a questionnaire and monthly assessments by a Infectious Disease physician.

Trial sites (1)

More University of Calgary trials in Canada

Other trials for the same condition